Muriel Richard

5PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Characterisation of biological macromoleculesToxicology (incl. clinical toxicology)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

|May 20, 2022
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients.

Marion Ort, Jasper Dingemanse, Chih-Hsuan Hsin

|Nov 18, 2020
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Benjamin Berger, Sander Brooks, Rob Zuiker

|Jan 30, 2020
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.

Muriel Richard, Priska Kaufmann, Marion Ort

|Apr 21, 2019
First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.

Muriel Richard, Priska Kaufmann, Rüdiger Kornberger

Pageof 1

Frequent Collaborators

3 joint publications

Jasper Dingemanse

2 joint publications

Priska Kaufmann

2 joint publications

Marion Ort

1 joint publications

Benjamin Berger